Engineered immune cells take aim at childhood cancer
NCT ID NCT07502287
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment for children and young adults with neuroblastoma that has returned or not responded to standard care. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack two different markers on the cancer cells. Participants receive chemotherapy first to prepare their immune system, then the engineered cells are given intravenously. The study aims to find the safest dose and see if the treatment can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (CAR-NK cells) that target two proteins on cancer cells
What this could lead to
If it works, this could offer a new treatment option for children with neuroblastoma that has come back or not responded to other therapies.
What could go wrong
This is an early-phase trial with only 36 participants, so it may not work for everyone. There are risks of side effects like immune reactions or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••